TY - JOUR
T1 - Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma
AU - The International Consortium on Meningiomas (ICOM)
AU - Wang, Justin Z.
AU - Patil, Vikas
AU - Landry, Alexander P.
AU - Gui, Chloe
AU - Ajisebutu, Andrew
AU - Liu, Jeff
AU - Saarela, Olli
AU - Pugh, Stephanie L.
AU - Won, Minhee
AU - Patel, Zeel
AU - Yakubov, Rebeca
AU - Kaloti, Ramneet
AU - Wilson, Christopher
AU - Cohen-Gadol, Aaron
AU - Zaazoue, Mohamed A.
AU - Tabatabai, Ghazaleh
AU - Tatagiba, Marcos
AU - Behling, Felix
AU - Almiron Bonnin, Damian A.
AU - Holland, Eric C.
AU - Kruser, Tim J.
AU - Barnholtz-Sloan, Jill S.
AU - Sloan, Andrew E.
AU - Horbinski, Craig
AU - Chotai, Silky
AU - Chambless, Lola B.
AU - Gao, Andrew
AU - Rebchuk, Alexander D.
AU - Makarenko, Serge
AU - Yip, Stephen
AU - Sahm, Felix
AU - Maas, Sybren L.N.
AU - Tsang, Derek S.
AU - Dincer, Alper
AU - Moliterno, Jennifer
AU - Passlack, Paul
AU - Schittenhelm, Jens
AU - la Fougère, Christian
AU - Santacroce, Antonio
AU - Renovanz, Mirjam
AU - Zada, Gabriel
AU - Hnenny, Luke
AU - Zherebitskiy, Viktor
AU - Malta, Tathiane M.
AU - Butowski, Nicholas A.
AU - Perry, Arie
AU - Raleigh, David R.
AU - Morokoff, Andrew
AU - Drummond, Katharine J.
AU - Felicella, Michelle M.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/11
Y1 - 2024/11
N2 - Treatment of the tumor and dural margin with surgery and sometimes radiation are cornerstones of therapy for meningioma. Molecular classifications have provided insights into the biology of disease; however, response to treatment remains heterogeneous. In this study, we used retrospective data on 2,824 meningiomas, including molecular data on 1,686 tumors and 100 prospective meningiomas, from the RTOG-0539 phase 2 trial to define molecular biomarkers of treatment response. Using propensity score matching, we found that gross tumor resection was associated with longer progression-free survival (PFS) across all molecular groups and longer overall survival in proliferative meningiomas. Dural margin treatment (Simpson grade 1/2) prolonged PFS compared to no treatment (Simpson grade 3). Molecular group classification predicted response to radiotherapy, including in the RTOG-0539 cohort. We subsequently developed a molecular model to predict response to radiotherapy that discriminates outcome better than standard-of-care classification. This study highlights the potential for molecular profiling to refine surgical and radiotherapy decision-making.
AB - Treatment of the tumor and dural margin with surgery and sometimes radiation are cornerstones of therapy for meningioma. Molecular classifications have provided insights into the biology of disease; however, response to treatment remains heterogeneous. In this study, we used retrospective data on 2,824 meningiomas, including molecular data on 1,686 tumors and 100 prospective meningiomas, from the RTOG-0539 phase 2 trial to define molecular biomarkers of treatment response. Using propensity score matching, we found that gross tumor resection was associated with longer progression-free survival (PFS) across all molecular groups and longer overall survival in proliferative meningiomas. Dural margin treatment (Simpson grade 1/2) prolonged PFS compared to no treatment (Simpson grade 3). Molecular group classification predicted response to radiotherapy, including in the RTOG-0539 cohort. We subsequently developed a molecular model to predict response to radiotherapy that discriminates outcome better than standard-of-care classification. This study highlights the potential for molecular profiling to refine surgical and radiotherapy decision-making.
UR - http://www.scopus.com/inward/record.url?scp=85205918205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205918205&partnerID=8YFLogxK
U2 - 10.1038/s41591-024-03167-4
DO - 10.1038/s41591-024-03167-4
M3 - Article
C2 - 39169220
AN - SCOPUS:85205918205
SN - 1078-8956
VL - 30
SP - 3173
EP - 3183
JO - Nature Medicine
JF - Nature Medicine
IS - 11
ER -